Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...
The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain to support the launch of its obesity pill orforglipron.
The Kanakee project builds on the company’s efforts to increase its U.S. footprint, where it has already spent more than $3 ...
The FDA’s actions have been unusual from the start of this leucovorin sage. The decades-old drug is often used to help cancer patients fight side effects of chemotherapy and other treatments that ...
The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...
Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...
Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many ...
The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...
The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.
The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.
Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...
Organizations that transition steady, high-volume lanes to engineered reusable systems often see 30–50% reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results